Mark Berger, M.D.

Dr. Berger is a senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.  Prior to joining Genprex in September 2021, Dr. Berger served as Chief Medical Officer for Actinium Pharmaceuticals, Inc. where he was responsible for clinical strategy and development of radioisotope-labeled antibodies for therapy in oncology. Before that, Dr. Berger was Senior Vice President-Clinical Research at Kadmon Corporation where he led all aspects of the company’s new drug development, including clinical trial design and management of the oncology programs in non-small cell lung cancer and breast cancer, among others.

Prior to that, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals. Before Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led the clinical strategy, design and management of clinical trials for two novel oncology agents.   Before that, Dr. Berger served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent.

Dr. Berger holds a B.A. in biology from Wesleyan University and a M.D. from the University of Virginia School of Medicine. He did his Hematology/Oncology fellowship at the University of Pennsylvania, where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology.

Achievements

• Successfully brought two drugs through the regulatory process to approval and excels in strategic development, team management and collaborative leadership
• Managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399-patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer